Affiliations 

  • 1 Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110013, China; Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah, Malaysia. Electronic address: hriday.bera1@gmail.com
  • 2 Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah, Malaysia
  • 3 Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India
  • 4 Agharkar Research Institute, Pune, Maharashtra, 411004, India
  • 5 Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110013, China
  • 6 Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110013, China; Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
Carbohydr Polym, 2020 Feb 15;230:115664.
PMID: 31887927 DOI: 10.1016/j.carbpol.2019.115664

Abstract

Erlotinib-loaded carboxymethyl temarind gum-g-poly(N-isopropylacrylamide)-montmorillonite based semi-IPN nanocomposites were synthesized and characterized for their in vitro performances for lung cancer therapy. The placebo matrices exhibited outstanding biodegradability and pH-dependent swelling profiles. The molar mass (M¯ c) between the crosslinks of these composites was declined with temperature. The solid state characterization confirmed the semi-IPN architecture of these scaffolds. The corresponding drug-loaded formulations displayed excellent drug-trapping capacity (DEE, 86-97 %) with acceptable zeta potential (-16 to -13 mV) and diameter (967-646 nm). These formulations conferred sustained drug elution profiles (Q8h, 77-99 %) with an initial burst release. The drug release profile of the optimized formulation (F-3) was best fitted in the first order kinetic model with Fickian diffusion driven mechanism. The mucin adsorption to F-3 followed Langmuir isotherms. The results of MTT assay, AO/EB staining and confocal analyses revealed that the ERL-loaded formulation suppressed A549 cell proliferation and induced apoptosis more effectively than pristine drug.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.